SRPK1 and non-small cell lung carcinoma: Chimeric antibody targeting SRPK‐1 inhibited mRNA expression levels of β‐catenin/T‐cell factor, matrix metalloproteinase‐9 (MMP‐9), collagen type I, and fibronectin in NSCLC‐derived vascular endothelial cells [194].